Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

Table 3 Comparison of efficacy for dabrafenib plus trametinib versus vemurafenib plus cobimetinib

Outcome	COMBI-v		coBRIM		ITC results
Outcome	D + T	V	V	V + C	HR/RR^a	LCI	UCI	p value
Overall survival, median (95% CI), months	25.6(22.6 − NR)	18.0(15.6 − 20.7)	17.4(15.0 − 19.8)	22.3(20.3 − NR)	0.94	0.68	1.30	0.7227
Progression-free survival, median (95% CI), months	12.6(10.7 − 15.5)	7.3(5.8 − 7.8)	7.2(5.6 – 7.5)	12.3(9.5 – 13.4)	1.05	0.79	1.40	0.7300
Overall response rate, no./total no. (%)	226/352(64%)	180/352(51%)	124/248(70%)	172/247(50%)	0.90	0.74	1.10	0.3029

^aFor D + T versus V + C; HR is the output for time-to-event outcomes, i.e., overall survival and progression-free survival; RR is the output for overall response rate
CI confidence interval, D + T dabrafenib plus trametinib, HR hazard ratio, NR not reached, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C vemurafenib plus cobimetinib

ISSN: 1756-8722